Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease

Loss of dopamine containing neurons in substantia nigra pars compacta of midbrain and resultant depletion of dopamine in striatum is the cause Parkinson ’s disease (PD) which is associated with motor abnormalities. Replenishment of dopamine by oral supplementation of its precursor, the levodopa (L-DOPA), remains the primary mode of treatment of PD despite its potential side-effects after prolonged use in patients. To reduce the daily dosing of L-D OPA in patients, inhibitors of dopamine catabolizing enzymes particularly monoamine oxidase-B (MAO-B) are prescribed.

Source: Medical Hypotheses - June 7, 2018 Category: Biomedical Science Authors: Muhammed Khairujjaman Mazumder, Rajib Paul, Banashree Chetia Phukan, Ankumoni Dutta, Jayasree Chakrabart, Pallab Bhattacharya, Anupom Borah Source Type: research